Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years. - Wikidata - wikimedia - TriplyDB

Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.

Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.

http://www.wikidata.org/entity/Q34266971

about

Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients.Patient's weight can decide about spending millions on enzyme replacement therapy in MPS II Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review.Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II.Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study.Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)Lysosomal Storage Disorders: Present and Future.Home infusion with Elosulfase alpha (VimizimR) in a UK Paediatric setting.

P2860

Q36571573-4CCD5C60-76E3-4296-B43A-1212E56DD966 Q36680631-AE56D563-8A7E-404F-A7D8-33A44D2BB317 Q38714026-E838FFBF-3D54-4408-BE50-37CD71B2C4AB Q39094272-7A385C21-FB0D-4C4E-A530-53694E538174 Q41700161-10BC933C-80C0-4967-B4A3-3BFB41A2F1BB Q42281140-B14AE426-CBFC-4614-807F-39D0C73FBE20 Q48271259-76D35F31-B780-4A70-BC4E-26D146D4A7A5 Q49850720-225FA37D-BD2B-43C4-A553-F563BEFCA27A

P2860

Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.

http://www.wikidata.org/entity/Q34266971

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@ast

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@en

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@nl

type

label

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@ast

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@en

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@nl

prefLabel

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@ast

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@en

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@nl

P1433

Q34266971-DE7CA3E3-A1A6-49BA-9F88-8D5C1B37891A

P1476

Q34266971-D94A4180-AD61-4310-9854-F9154545E9E1

P2093

Q34266971-089C0CB9-8005-4862-86AE-35E31FF9BE72

Q34266971-182C6505-6F27-4DD9-9041-1BDC021123E6

Q34266971-2AD7B905-F8EB-482F-B1A6-19D59362F249

Q34266971-350B68D2-BC03-4AB8-8288-BF2FEF997122

Q34266971-4DD7E184-FE0D-469A-8095-3E1EFAF8E67D

Q34266971-63CD2426-AF68-4C82-B66E-ADB651E2B056

Q34266971-7A7D21D9-D0D5-4909-A491-3E9137C3C395

Q34266971-8ED3FC8D-2FC1-46CC-8819-900453653126

Q34266971-B819E942-C289-4349-B803-8C66CD8A1817

Q34266971-BB1DB04E-838B-40AC-8567-EFFB72AC48FE

P2860

Q34266971-056BED2E-70C1-4AB9-8A60-1EC8CF98C3BC

Q34266971-07227C97-90C9-4FD9-B578-6152C2CAFF80

Q34266971-09D4C4A3-2540-4038-9AAA-C396A8522D85

Q34266971-0FE8F29D-20E3-453A-BC7A-7D4FE17A65FF

Q34266971-11474AB1-6950-4894-8C2F-1352F2622929

Q34266971-1907742E-0124-4ADF-8834-2BF8932FFB93

Q34266971-198558AA-768A-4698-B4F6-B909A9AB2985

Q34266971-20A9C706-9352-4D3B-99F2-B6C98BA13669

Q34266971-2155AE9B-8137-4714-ADB1-65FF8D4341B8

Q34266971-2B05E845-74AB-4CB4-A536-6F88F981938D

P2888

Q34266971-07CDE476-65DF-4D23-BD8D-0C8848C71344

P304

Q34266971-DAB9FAA7-E964-4778-A5C2-1F0822BD5825

P31

Q34266971-AC49E8B2-6250-402C-A430-F196187DAB8D

P356

Q34266971-C7F3A445-A432-4A26-8D83-851FD658480C

P478

Q34266971-B58134D9-B4D1-4455-861A-15440867E87B

P50

Q34266971-3BEBBF81-BDD2-49BC-89B6-DE432996D50A

P577

Q34266971-3EE264EC-92A3-40FA-BE14-D8D11895AEB5

P5875

Q34266971-628D5BEA-8015-486F-89D3-9448FD83FF65

P6179

Q34266971-86917121-938F-4580-862F-8094B703C75A

P698

Q34266971-B19D6FF2-0468-48C1-AD3D-83066067DA83

P921

Q34266971-9EE86FDA-34FC-4442-BE03-826E14E25BBE

P932

Q34266971-85FF1348-87A9-4115-A9B4-137308428A77

P356

S13023-014-0129-1

P1433

Orphanet Journal of Rare Diseases

P1476

Clinical efficacy of enzyme re ...... ndependent study of 3.5 years.

@en

P2093

Agata Fiumara

http://www.w3.org/2001/XMLSchema#string

Alessandra Zanetti

http://www.w3.org/2001/XMLSchema#string

Andrea Borgo

http://www.w3.org/2001/XMLSchema#string

Angelica Rampazzo

http://www.w3.org/2001/XMLSchema#string

Anna Chiara Frigo

http://www.w3.org/2001/XMLSchema#string

Antonia Pascarella

http://www.w3.org/2001/XMLSchema#string

Daniela Concolino

http://www.w3.org/2001/XMLSchema#string

Elena Procopio

http://www.w3.org/2001/XMLSchema#string

Francesca D'Avanzo

http://www.w3.org/2001/XMLSchema#string

Maurizio Scarpa

http://www.w3.org/2001/XMLSchema#string

P2860

Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)

Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

A clinical study of 77 patients with mucopolysaccharidosis type II

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms.

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy.

Pricing and reimbursement of orphan drugs: the need for more transparency

The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS).

P2888

s13023-014-0129-1

P304

129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13023-014-0129-1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Rossella Parini

P577

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265791856

http://www.w3.org/2001/XMLSchema#string

P6179

1024289668

http://www.w3.org/2001/XMLSchema#string

P698

25231261

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

4180060

http://www.w3.org/2001/XMLSchema#string